Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Public Equity Report: Erasca reboots, Telix plans NASDAQ listing

Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback

May 17, 2024 7:05 PM UTC

Less than two months after tapping investors for a PIPE, Erasca Inc. (NASDAQ:E RAS) has raised $160 million in a public offering announced concurrently with a pair of licensing deals for RAS programs, resetting the company’s priorities.

Late Thursday, the biotech sold 86.5 million shares at $1.85, at parity with its closing price. Following Erasca’s $45 million PIPE from undisclosed investors in March, the company now believes it has cash runway into 2027...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article